e-Therapeutics shares jump following 40m equity issue

Drug discovery and development company e-Therapeutics is proposing to raise 40m pounds through an issue of new ordinary shares to existing and new institutional investors.

Drug discovery and development company e-Therapeutics is proposing to raise 40m pounds through an issue of new ordinary shares to existing and new institutional investors.

The new shares will be priced at 32p, a premium of 4.0% to the closing mid-market price on Friday.

Following the proposed issue, the company will have a pro-forma net cash and liquid resources of approximately £48m.

According to the the company's update, the resources are intended to support its currently planned discovery and development activities to 2017, by which time, it said it believed that an out-licensing deal could be concluded for the company's lead cancer drug ETS2101.

Professor Malcolm Young Chief Executive Officer of e-Therapeutics, said: "We appreciate the continuing support of existing investors and are also pleased to have attracted significant new investors to the company. With our financial position secure, we are well-placed to build further shareholder value based on our innovative platform and product portfolio."

e-Therapeutics' share price was up 4.88% to 32.25p at 09:03 on Monday.

MF

Recommended

How to be better at selling stocks
Investment strategy

How to be better at selling stocks

There is plenty of advice around about buying stocks, but not so much about when you should sell. John Stepek explains the two key things to know abou…
14 Jan 2022
Share tips of the week – 14 January
Share tips

Share tips of the week – 14 January

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
14 Jan 2022
Fintech: how to profit as technology transforms banking around the world
Share tips

Fintech: how to profit as technology transforms banking around the world

Financial technology – from apps to APIs to the cloud – is rapidly transforming financial services. This will spell doom for some incumbent firms, whi…
14 Jan 2022
Three solid assets to buy for a low interest-rate world
Share tips

Three solid assets to buy for a low interest-rate world

Professional investor Luke Hyde-Smith of the Waverton Real Assets Fund, highlights three alternative investments to diversify your portfolio.
14 Jan 2022

Most Popular

Five unexpected events that could shock the markets in 2022
Stockmarkets

Five unexpected events that could shock the markets in 2022

Forget Covid-19 – it’s the unexpected twists that will rattle markets in 2022, says Matthew Lynn. Here are five possibilities
31 Dec 2021
Which investment trusts performed the best in 2021?
Investment trusts

Which investment trusts performed the best in 2021?

Shivani Khandekar runs through the top ten investment trusts of 2021 – and the worst performing trusts – and looks ahead to 2022.
7 Jan 2022
Interest rates might rise faster than expected – what does that mean for your money?
Global Economy

Interest rates might rise faster than expected – what does that mean for your money?

The idea that the US Federal Reserve could raise interest rates much earlier than anticipated has upset the markets. John Stepek explains why, and wha…
6 Jan 2022